🇺🇸 SPECTINOMYCIN HYDROCHLORIDE in United States

FDA authorised SPECTINOMYCIN HYDROCHLORIDE on 30 June 1971 · 6 US adverse-event reports

Marketing authorisations

FDA — authorised 30 June 1971

  • Application: NDA050347
  • Marketing authorisation holder: PFIZER
  • Local brand name: TROBICIN
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Hypersensitivity — 1 report (16.67%)
  2. Loss Of Consciousness — 1 report (16.67%)
  3. Malaria — 1 report (16.67%)
  4. Muscle Spasms — 1 report (16.67%)
  5. Pruritus — 1 report (16.67%)
  6. Rash — 1 report (16.67%)

Source database →

SPECTINOMYCIN HYDROCHLORIDE in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is SPECTINOMYCIN HYDROCHLORIDE approved in United States?

Yes. FDA authorised it on 30 June 1971; FDA has authorised it.

Who is the marketing authorisation holder for SPECTINOMYCIN HYDROCHLORIDE in United States?

PFIZER holds the US marketing authorisation.